Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen

Prostate

Volumn 29, Issue SUPPL. 7, 1996, Pages 48-57

  Van Iersel, M P ^a   Witjes, W P J ^a   Thomas, C M G ^a   Segers, M F G ^a   Oosterhof, G O N ^a   Debruyne, F M J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antichymotrypsin; benign prostate hyperplasia; complexed; free; prostate specific antigen; prostatic carcinoma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; STANDARDIZATION; BIOPSY; CANCER STAGING; ENZYME IMMUNOASSAY; FLUOROMETRY; IMMUNOASSAY; METABOLISM; METHODOLOGY; PATHOLOGY; PHLEBOTOMY; PHYSIOLOGY; POSTOPERATIVE PERIOD; PROSTATE; PROSTATE TUMOR; REVIEW;

BIOPSY; FLUOROMETRY; HUMANS; IMMUNOASSAY; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM STAGING; PHLEBOTOMY; POSTOPERATIVE PERIOD; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030340814     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(1996)7+<48::AID-PROS7>3.0.CO;2-F     Document Type: Conference Paper

References (66)

1. Boring C, Squires T, Tong T, Montgomery S: Cancer statistics. CA 44:7-26, 1994.
2. Jewett H: Radical perineal prostatectomy for palpable, clinically localized, non-obstructive cancer: Experience at the John Hopkins Hospital 1909-1963. J Urol 124:492-494, 1980.
3. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM: A prostate antigen in sera of prostatic cancer patients. Cancer Res 40:2428, 1980.
4. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD: Prostate cancer detection in clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146-1154, 1990.
5. Kramer BS, Brown ML, Prolok PC, Potosky AL, Gohagan JK: Prostate cancer screening: What we know and what we need to know. Ann Intern Med 119:914-923, 1993.
6. Benson MC, Whang IS, Pantuck, A, Ring K, Kaplan SA, Olsson CA, Cooner WH: Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147:815-816, 1992.
7. Catalona WJ, Richie JP, de Kernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT, Southwick PC: Comparison of prostate specific antigen concentration versus prostate specific antigen density in early detection of prostate cancer: Receiver operating characteristic curves. J Urol 152:2031-2036, 1994.
8. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Liebner MM: Influence of patient age on the serum PSA concentration: An important clinical observation. Urol Clin North Am 20:671-680, 1993.
9. Carter HD, Pearson JD: PSA velocity for the diagnosis of early prostate cancer: A new concept. Urol Clin North Am 20:665-670, 1993.
10. Carter HB, Pearson JD, Wacliwew X, Metter EJ, Guess HA, Walsh PC: PSA variability in men with BPH. J Urol 151:312, 1994.
11. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916, 1987.
12. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, de Kernion JB, Ratliff TL, Kavoussi LR, Dalkin BL: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves. J Urol 152:2037-2042, 1994.
13. Hara M, Koyanagi Y, Inoue T, Fukuyama T: Some physico-chemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. Nippon Hoigaku Zasshi 25:322-324, 1971.
14. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol 17:159-163, 1979.
15. Sensabaugh GH: Isolation and characterization of a semen-specific protein from human seminal plasma: A potential new marker for semen identification. J Forensic Sci 23:106, 1978.
16. Schellhammer P, Wright G Jr: Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Urol Clin North Am 20:597-606, 1993.
17. Christensson A, Lilja H: Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human serum. Eur J Biochem 220:45-53, 1994.
18. Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochem 194:755-763, 1990.
19. Leinonen J, Zhang WM, Stenman UH: Complex formation between PSA isoenzymes and protease inhibitors. J Urol 155:695, 1996.
20. Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T: Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 37:1618-1625, 1991.
21. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222-226, 1991.
22. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen M, Cockett ATK, Abrahamsson PA, Lilja H: Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 150:100-105, 1993.
23. Henttu P, Vihko P: cDNA coding for the entire human prostate specific antigen shows high homologies to the tissue kallikrein genes. Biochem Biophys Res Commun 160:903-910, 1989.
24. Dephertes D, Chapdelaine P, Tremblay RR, Brunet C: Isolation of prostatic Kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochem Biophys Acta 1245:311-316, 1995.
25. Piironen T, Lövgren J, Karp M, Eerola R, Lundwall Å, Dowell B: Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity. Clin Chem 213:888-895, 1995.
26. Agha AH, Schechter E, Roy JB, Culkin DJ: Prostate specific antigen is metabolized in the liver. J Urol 155: 379, 1996.
27. Partin A, Subong ENP, Kelley CA, Hortopan S, Carter B, Chan DW, Walsh PC: Prospective analysis of free PSA to total PSA ratio (PSAf/PSAt) for prostate cancer determination and the clearance rate of PSAf after radical prostatectomy. J Urol 155:416, 1996.
28. Wood WG, van der Sloot E, Böhle A: The establishment and evaluation of luminescent-labelled immunometric assays for prostate-specific antigen-α1-antichymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 29:787-794, 1991.
29. Stamey TA, Chen Z, Prestigiacomo AF: Serum prostate specific antigen binding: Influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 152:1510-1514, 1994.
30. Pettersson K, Piironen T, Seppälä M, Liukkonen L, Christensson A, Matikainen MT, Suonpää M, Lövgren T, Lilja H: Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-α1-antichymotrypsin complex. Clin Chem 41:1480-1488, 1995.
31. Björk T, Bjartell A, Lilja H, Abrahamsson PA, di Sant'Agnese A: Occurrence of α1-antichymotrypsin in the PSA-producing prostatic epithelium may be a prerequisite for complex-binding of PSA to α1-antichymotrypsin in blood. J Urol 149:332, 1993.
32. Bostwick DG, Oesterling JE, MacLennan G, Pacelli A, Abrahammson PA, Lilja H: PSA and alpha-1-antichymotrypsin expression in prostatic intraepithelial neoplasia and adenocarcinoma. J Urol 155:625, 1996.
33. Igawa M, Urakami S, Shiina H, Ishibe T, Shirane T, Usui T, Chodak GW: Immunohistochemical evaluation of proliferating cell nuclear antigen, prostate-specific antigen and α1-antichymotrypsin in human prostate cancer. Br J Urol 77:107-112, 1996.
34. Chen Z, Chen H, Stamey TA: Prostate specific antigen (PSA) in benign prostatic hyperplasia (BPH) tissue is different from PSA in prostate cancer (PCa) tissue. J Urol 155:696, 1996.
35. Brawer MK, Wener MK, Rittenhouse HG, Wolfert RL: Proportion of free form of PSA explains the majority of bias between the IMx (Abbott) and Tandem (Hybritech) PSA assays. J Urol 155:416, 1996.
36. Semjonow A, Oberpenning F, Brandt B, Hertle L: Influence of the free PSA fraction on the measurement of 7 different assays for total PSA. J Urol 155:420, 1996.
37. Chen Z, Prestigiacomo AF, Stamey TA: Purification and characterization of prostate-specific antigen (PSA complexed to alpha 1-antichymotrypsin): Potential reference material for international standardization of PSA immunoassays. Clin Chem 41:1273-1282, 1995.
38. Oesterling JE, Rice D, Glenski WJ, Bergstralh EJ: Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 42:276-282, 1993.
39. Glenski WJ, Klee GG, Bergstralh EJ, Oesterling JE: Prostate-specific antigen: Establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations. Prostate 21:99-110, 1992.
40. Collins GN, Napier-Hemey R, Martin PJ, Brooman PJ, O'Reilley P: Characteristics of free PSA activity in clinical urological practice. J Urol 155:421, 1996.
41. Herschman D, Smith DS, Catalona WJ: Effect of ejaculation on free and total PSA levels. J Urol 155:423, 1996.
42. Neal DE Jr, Clejan S, Sarma D, Moon TD: Prostate-specific antigen and prostatitis. I: Effect of prostatitis in serum PSA in the human and nonhuman primate. Prostate 20:105-111, 1992.
43. Woodrum D, French C, Shamel LB, Roman S: Stability of free PSA in serum. J Urol 155:421, 1996.
44. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lovgren T, Lilja H: Free, complexed and total serum prostate specific antigen: The establishment of appropriate refernce ranges for their concentrations and ratios. J Urol 154:1090-1095, 1995.
45. Klee GG, Lerner SE, Jacobsen SJ, Bergstralh EJ, Lilja H, Pettersson K, Guess HA, Lieber MM, Oesterling JE: Predictive power of free:total PSA ratio is not superior to total PSA in the diagnosis of prostate cancer in the community setting. J Urol 155:371, 1996.
46. Flemming C, Barry MJ, Oesterling JE: Prostate-specific antigen (PSA) age specific reference ranges versus a single threshold: Is the best answer to bypass PSA and biopsy everyone? J Urol 155:452, 1996.
47. Yemoto CM, Nolley R, Prestigiacomo AF, Stamey TA: Free (f) and total (t) PSA density in patients with prostate cancer (CaP) and benign prostatic hyperplasia (BPH). J Urol 155:374, 1996.
48. Gleave ME, Coupland D, Drachenberg D, Cohen L, Kwong S, Goldberg SL, Sullivan LD: Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed cancer. Urology 47:708-712, 1996.
49. Bleustein D, Bostwick D, Bergstralh E, Oesterling J: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 151: 1315-1320, 1994.
50. Hendricks WH, England BG, Giacherio DA, Oesterling JE, Wojno KJ: Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma. J Urol 155:369, 1996.
51. Lerner SE, Jacobsen SJ, Bergstralh EJ, Klee GG, Blute ML, Lieber MM, Zincke H, Lilja H, Oesterling JE: Free, complexed and total serum PSA concentrations and their proportions in predicting stage, grade, and DNA ploidy in patients with prostate cancer (PC). J Urol 155: 416, 1996.
52. Partin AW, Subong ENP, Jones KA, Marschke PLS, Epstein JI, Chan DW, Carter HB, Luderer AA: Free/ total PSA does not improve the prediction of final pathological stage for men with localized prostate cancer. J Urol 155:415, 1996.
53. Graefen M, Hammerer P, Henke P, Hilz H, Huland E, Huland H: Percentage of free PSA does not correlate with pathological outcome. J Urol 155:370, 1996.
54. Arcangeli CG, Shepherd LD, Smith DS, Humphrey PA, Keetch DW, Catalona WJ: Correlation of percent free PSA with pathologic features of prostatic carcinoma. J Urol 155:415, 1996.
55. Israeli RS, Miller WH Jr, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, DeBlasio A, Edwards ET, Wise GJ: Sensitive nested polymerase chain reaction of circulating prostatic antigen-based assays. Cancer Res 54: 6306-6310, 1994.
56. Sokoloff M, Tso C, Franklin J, Nelson S, Dorey F, de Kernion J, Belldegrun A: Quantitative polymerase chain reaction (PCR) does not improve prostate cancer (PC) staging: A clinical pathologic-molecular analysis of 121 patients. J Urol 155:417, 1996.
57. Elgamal AA, Cornillie F, van Poppel H, van Dorpe JO, Gero E, Haberzetti C, McCabe R, Baert LV: Free/total PSA ration (F/T) as a single test for detection of significant T1c prostate cancer. J Urol 155:369, 1996.
58. Oesterling JE, Wojno KJ, England B: A comparison of free to total PSA (F/T) ratio to total PSA for distinguishing benign prostatic hyperplasia (BPH) from prostate cancer (CaP) using the Abbottt AxSYM system. J Urol 155:370, 1996.
59. Sagalowsky AI, Wiams FH, Jialal I, Roehrborn CG: Ability of the ratio between free and total prostate specific antigen (PSA) and different PSA assays to predict ultimate histological diagnosis of prostatic tissue. J Urol 155:420, 1996.
60. Saito S, Ozu C, Nakamura K, Tachibana M, Baba S, Ishibashi M, Ohtake T, Kano S, Murai M: Screening of prostate cancer with free and total prostate specific antigen (PSA) ratio. J Urol 155:373, 1996.
61. Reissigl A, Klocker H, Pointner J, Ennemoser O, Fink K, Bartsch G: Improvement of prostate cancer (PCA) in screening by determination of the free/total (FT) PSA in addition to PSA levels, a prospective study. J Urol 155: 370, 1996.
62. Petteway JC, Brawer MK, Meyer GE: Comparison of two investigative assays for the free form of PSA. J Urol:371, 1996.
63. Smith DS, Catalona WJ, Keetch DW: Comparison of percent free PSA and PSA density to enhance the specificity of PSA screening. J Urol 155:422, 1996.
64. Marley GM, Patton KP, Miller MC, Zhao G, Veltri RW, Kattan MW, Wright GR, Schellhammer PF, Vessella RL: Free/total prostate specific antigen (PSA) serum ratio predicts probability of cancer diagnosis in patients with elevated total PSA. J Urol 155:422, 1996.
65. Van Cangh PJ, Denayer P, Sauvage P, Opsomer R, Lorge F, Tombal B, Wese FX: Clinical value of free/total prostate specific antigen ratio: Data from 453 histologically confirmed prostate tumors. J Urol 155:534, 1996.
66. f after radical prostatectomy. J Urol 155:416, 1996.